AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...
Key growth factors for KEYTRUDA include its unparalleled commercial scale, broad approval across multiple tumor types, strong uptake in early-stage therapies, and a robust clinical trial program.
Zacks Investment Research on MSN
Will Keytruda continue to aid MRK's growth in 2026 after a strong Q1?
Merck’s MRK strong oncology sales growth is largely driven by its biggest revenue driver, Keytruda. The blockbuster PD-L1 ...
Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA ...
Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the ...
(Reuters) -Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset falling sales from human papillomavirus vaccine Gardasil in China.
Mounjaro surpasses Keytruda top sales with $8.7B in Q1 2025, marking a 125% increase for Eli Lilly over Merck's cancer drug.
(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...
Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro has surpassed Merck & Co.’s cancer therapy Keytruda as the world’s ...
On the second night of the largest annual European cancer conference, some 100 Merck scientists packed into Champeaux, a classic French restaurant, to break bread and share clinical wisdom. It was ...
Mounjaro surpassed Keytruda as the world’s top-selling medicine, driven by soaring global demand for obesity and diabetes ...
Merck & Co., Inc. (NYSE:MRK) is a global health care company working to deliver innovative health solutions through our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results